Management of Urge Urinary Incontinence: Evidence‑Based Recommendations

First‑Line Behavioral Interventions

• Bladder training should be offered to all women with urge urinary incontinence as the initial therapy; this is a strong recommendation supported by moderate‑quality evidence. 1
• Behavioral approaches are effective, have minimal adverse effects, and are less costly than pharmacologic options. 1
• Scheduled voiding with progressive interval increases (bladder training) suppresses urgency. 2
• Reducing total fluid intake by about 25 % decreases urinary frequency and urgency. 2
• Limiting caffeine consumption lowers voiding frequency. 2
• In obese patients, an approximate 8 % weight loss reduces urgency incontinence episodes by roughly 42 %. 2
• Overall, behavioral therapies are equivalent to or superior to medications for reducing incontinence episodes, improving frequency, and enhancing quality of life. 2

Second‑Line Pharmacologic Therapy

• Pharmacologic treatment should be added only after bladder training has proven unsuccessful. 1
• All antimuscarinic agents and β‑3 agonists demonstrate similar efficacy, providing a moderate benefit for achieving continence. [1][3]
• Medication choice should be guided by tolerability and adverse‑effect profile rather than efficacy differences. 1

Preferred Initial Agents (lowest discontinuation rates)

• Darifenacin or tolterodine have discontinuation rates comparable to placebo. [4][5]
• Mirabegron (β‑3 agonist) is typically preferred before antimuscarinics because it carries a lower risk of cognitive impairment. 3

Agents with Higher Discontinuation Risks

• Solifenacin shows the lowest discontinuation risk among agents that exceed placebo (Number Needed to Harm = 78). 5
• Fesoterodine has a Number Needed to Harm of 33 for discontinuation. 5
• Oxybutynin has the highest discontinuation rate (Number Needed to Harm = 16) and should be avoided as a first‑choice agent. 5

Safety and Contra‑indications

• Patients prescribed antimuscarinics must be counseled about the potential risk of incident dementia; meta‑analyses indicate a cumulative, dose‑dependent association. 3
• Absolute contraindication: narrow‑angle glaucoma (unless cleared by an ophthalmologist). 2
• Use with extreme caution in individuals with impaired gastric emptying or a history of urinary retention. 2
• Additional caution is warranted for patients with diabetes, prior abdominal surgery, narcotic use, scleroderma, hypothyroidism, Parkinson’s disease, or multiple sclerosis. 3
• Common antimuscarinic adverse effects include dry mouth, constipation, and blurred vision (Number Needed to Harm ranges from 6 to 12 depending on the specific agent). [6][7]
• Mirabegron may cause nasopharyngitis and gastrointestinal disturbances. 6
• Tolterodine carries a risk of hallucinations. 7

Combination Therapy

• Behavioral therapies can be combined with pharmacologic treatment for additive benefit. 2
• When adding a second modality, introduce one intervention at a time to assess its individual impact. 3
• If no improvement is observed with combined therapy, discontinue one or both treatments and consider alternative options. 3

Treatment Algorithm Summary

Common Pitfalls to Avoid

• Skipping behavioral therapy misses an equally effective and safer first‑line option. 1
• Assuming efficacy differences among medications is incorrect; selection should be based on side‑effect profiles. 1
• Ignoring cognitive risks in older adults can lead to dementia; β‑3 agonists are preferred in this population. 3
• Prescribing antimuscarinics without screening for contraindications (e.g., glaucoma, gastric emptying issues, urinary retention) should be avoided. 2

Management of Bladder Spasms in Urgency Urinary Incontinence and Overactive Bladder

First‑Line Non‑Pharmacologic Therapy

Pharmacologic Options and Discontinuation Risks

Efficacy Comparison Across Drug Classes

Treatment of Neurogenic Bladder Dysfunction

Common Adverse Effects of Antimuscarinics and β‑3 Agonists

Combination Therapy Strategies

Adherence and Discontinuation Considerations

Guideline for Management of Urge Urinary Incontinence (Cited Evidence)

Initial Assessment

• Screen all patients for urinary tract infection with urinalysis and culture before initiating treatment to eliminate a reversible cause of urgency. 13
• Review current medications for agents that can exacerbate incontinence (e.g., diuretics, α‑blockers, sedatives, anticholinergics) and consider modification. 13, 14
• Assess for metabolic disorders (diabetes, hypercalcemia), excess fluid intake, delirium, and chronic constipation as potential contributors to urgency. 13, 14
• Proactive case‑finding is essential because ≥ 50 % of incontinent women do not report symptoms, especially those > 65 years, nursing‑home residents, or home‑care recipients. 13, 14

First‑Line Behavioral Therapy (Mandatory Before Medications)

• Bladder training is the required first‑line intervention; it yields symptom improvement that is equivalent to or superior to pharmacologic therapy, with minimal adverse effects and lower cost. 13, 14
• Weight reduction of 5–10 % in obese patients (BMI ≥ 30 kg/m²) reduces urgency episodes by ≈ 42 %. 13, 14
• Adding pelvic‑floor muscle training to bladder training for pure urgency provides no additional benefit and should be avoided. 13, 14

Pharmacologic Therapy (Second‑Line, After Failed Bladder Training)

• All antimuscarinic agents and β‑3 agonists have comparable efficacy, producing similar reductions in urgency episodes and continence rates; drug choice should be driven by tolerability and side‑effect profile. 13, 14, 15
• Mirabegron (β‑3 agonist) is preferred before antimuscarinics because it carries a lower risk of cognitive impairment and dementia. 15
• Tolterodine and darifenacin have discontinuation rates comparable to placebo, making them acceptable first‑line antimuscarinics. 13, 14
• Oxybutynin should never be used as first‑line therapy; it has the highest discontinuation rate (NNTH = 16) due to dry mouth, constipation, and blurred vision. 13, 14
• Fesoterodine also has a high discontinuation rate (NNTH = 33) and is not recommended as first‑line. 13
• Common antimuscarinic adverse effects (dry mouth, constipation, blurred vision) have NNTH values ranging from 6 to 12, varying by agent. 13, 14
• Long‑term antimuscarinic use is associated with a dose‑dependent increase in incident dementia and cognitive impairment; patients should be counseled about this risk. 15
• Mirabegron’s typical adverse effects include nasopharyngitis and gastrointestinal disturbances. 13, 14

Contraindications and Cautions

• Absolute contraindication: narrow‑angle glaucoma (unless cleared by ophthalmology). 15
• Use with extreme caution in patients with a history of urinary retention, impaired gastric emptying, diabetes, prior abdominal surgery, narcotic use, scleroderma, hypothyroidism, Parkinson’s disease, or multiple sclerosis. 15

Combination Therapy

• When bladder training alone is insufficient, add pharmacotherapy rather than replace it; the combination yields additive benefit. 15
• Introduce one intervention at a time to allow assessment of each modality’s individual impact. 15
• If combined therapy fails to produce improvement, discontinue one or both interventions and consider third‑line options. 15

Third‑Line Therapies (Refractory Cases)

• Intravesical onabotulinum toxin‑A injections are an option for patients unresponsive to behavioral and pharmacologic measures. 13
• Sacral neuromodulation may be employed for refractory urgency incontinence. 13
• Posterior tibial nerve stimulation is another viable third‑line modality. 13

Critical Pitfalls to Avoid

• Do not initiate treatment with medications; behavioral therapy provides equal or superior outcomes with fewer adverse effects and lower cost. 13, 14
• Do not assume efficacy differences among antimuscarinics or β‑3 agonists; all have comparable effectiveness, so selection should be based on side‑effect profiles. 13, 14, 15
• Never use oxybutynin as a first‑line agent because of its high discontinuation rate (NNTH = 16). 13, 14
• Always counsel patients about the dementia risk associated with long‑term antimuscarinic use, especially older adults. 15
• Screen for narrow‑angle glaucoma, urinary retention risk, and impaired gastric emptying before prescribing antimuscarinics. 15
• Address reversible causes (UTI, offending medications, metabolic disorders, delirium) before definitive therapy. 13, 14

Treatment Algorithm Summary